Comparison of two dose regimens of growth hormone (GH) with different target IGF-1 levels on glucose metabolism, lipid profile, cardiovascular function and anthropometric parameters in gh-deficient adults

Growth Hormone and IGF Research

Volumn 22, Issue 3-4, 2012, Pages 116-121

  Cenci, Maria Claudia Peixoto ^a   Soares, Débora Vieira ^a   Spina, Luciana Diniz Carneiro ^a   Brasil, Rosane Resende de Lima Oliveira ^a   Lobo, Priscila Marise ^a   Michmacher, Eduardo ^a   Vaisman, Mario ^a   Boguszewski, Cesar Luiz ^b   Conceição, Flávia Lúcia ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

GH deficiency in adults; GH substitution; Hypopituitarism

Indexed keywords

DESMOPRESSIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; INSULIN; LEVOTHYROXINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISONE; SOMATOMEDIN C; STEROID; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; BRAZIL; CARDIOVASCULAR FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HUMAN; INSULIN BLOOD LEVEL; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT CHANGE;

ADULT; ANTHROPOMETRY; BLOOD GLUCOSE; BODY COMPOSITION; BRAZIL; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 84863782742     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2012.04.002     Document Type: Article

References (42)

1. Gibney J., Wallace J.D., Spinks T., et al. The effects of 10years of recombinant human growth hormone (GH) in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 1999, 84:2596-2602.
2. Götherström G., Svensson J., Koranyi J., et al. A prospective study of 5years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass and metabolic indices. J. Clin. Endocrinol. Metab. 2001, 86:4657-4665.
3. Weaver J.U., Monson J.P., Noonan K., et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J. Clin. Endocrinol. Metab. 1995, 80:153-159.
4. Al-Shoumer K.A.S., Gray R., Anyaoku V., et al. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin. Endocrinol. 1998, 48:795-802.
5. Johannsson G., Rosen T., Bergtsson B.-A. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin. Endocrinol. 1997, 47:571-581.
6. Drake W.M., Coyte D., Camacho-Hubner N.M., et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J. Clin. Endocrinol. Metab. 1998, 83:3913-3919.
7. Gillberg P., Bramnert M., Thorén M., Werner S., Johannsson G. Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function. Growth Horm. IGF Res. 2001, 11:273-281.
8. Molitch M.E., Clemmons D.R., Malozowski S., Merriam G.R., Shalet S.M., Vance M.L. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96:1587-1609.
9. Popovic V., Mattsson A.F., Gaillard R.C., Wilton P., Koltowska-Haggstron M., Ranke M.B. Serum insulin-like growth factor I (IGF-1), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). J. Clin. Endocrinol. Metab. 2010, 95:4449-4454.
10. Cannavó S., Marini F., Curtó L., Torre M.L., de Gregorio C., Salamone I., Alibrandi A., Trimarchi F. High prevalence of coronary calcifications and increased risk for coronary heart disease in adults with growth hormone deficiency. J. Endocrinol. Invest. 2011, 34:32-37.
11. The Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197.
12. Mathews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
13. Sahn D.J., DeMaria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiography of a survey of echocardiographic measurements. Circulation 1978, 58:1072-1083.
14. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 1986, 57:450-458.
15. Friedewald W.T., Levy R.I., Friedrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
16. Boguszewski C.L., Meister L.H., Zaninelli D.C., Radominski R.B. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur. J. Endocrinol. 2005, 152:67-75.
17. Ho K.K., GH Deficiency Consensus Workshop Participants Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur. J. Endocrinol. 2007, 157:695-700.
18. Spielhagen C., Schwahn C., Moller K., et al. The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Horm. IGF Res. 2011, 21:1-10.
19. Chrisoulidou A., Beshyah S.A., Rutherford O., et al. Effects of 7years of growth hormone replacement therapy in hypopituitary adults. J. Clin. Endocrinol. Metab. 2000, 85:3762-3769.
20. Hwu C.M., Kwok C., Lai T.Y., et al. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J. Clin. Endocrinol. Metab. 1997, 82:3285-3292.
21. Spina L.D.C., Soares D.V., Brasil R.R.L.O., Silva E.M.C., Lobo P.M., Conceição F.L., Vaisman M. Glucose metabolism and visceral fat in GH deficient adults: 1year of GH replacement. Growth Horm. IGF Res. 2004, 14:45-51.
22. Rosenfalck A.M., Maghsoudi S., Fisker S., et al. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J. Clin. Endocrinol. Metab. 2000, 85:4173-4418.
23. Svensson J., Fowelin J., Landin K., Bengtsson B.-Å., Johansson J.-O. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J. Clin. Endocrinol. Metab. 2002, 87:2121-2127.
24. Bulow B., Erfurth E.M. A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance. Clin. Endocrinol. 1999, 50:45-55.
25. Maison P., Griffin S., Nicoue-Beglah M., Haddad N., Balkau B., Chanson P. Impact of growth-hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J. Clin. Endocrinol. Metab. 2004, 89:2192-2199.
26. Cenci M.C.P., Conceição F.L., Soares D.V., Spina L.D.C., Brasil R.R.L.O., Lobo P.M., Michmacher E., Vaisman M. Impact of 5years of growth hormone replacement therapy on cardiovascular risk factors in GH-deficient adults. Metabolism Clinical and Experimental 2008, 57:121-129.
27. Yuen K.C., Frystyk J., White D.K., et al. Improvements in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone dose in adults with severe GH deficiency. Clin. Endocrinol. 2005, 63:428-436.
28. Yuen K.C., Dunger D.B. Persisting effects on fasting glucose levels and insulin sensitivity after 6months of discontinuation of a very low-dose GH therapy in adults with severe GH deficiency. Clin. Endocrinol. 2006, 64:549-555.
29. Abrams P., Boquete H., Fideleff H., et al. GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables. Eur. J. Endocrinol. 2008, 159:825-832.
30. Attanasio A.F., Bates P.C., Ho K.K.Y., et al. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status-3-year results from the HypoCCS Database. J. Clin. Endocrinol. Metab. 2002, 87:1600-1606.
31. Garry P., Collins P., Devlin J.D. An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adults acquired growth hormone deficiency. Eur. J. Endocrinol. 1996, 134:61-66.
32. Jorgensen A.P., Fougner K.J., Ueland T., et al. Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Horm. IGF Res. 2011, 21:69-75.
33. Leese G.P., Wallymahmed M., Wieringa G., Van Heyningen C., MacFarlane I.A. Apo E phenotype and changes in serum lipids in adult patients during growth hormone replacement. Eur. J. Endocrinol. 1999, 140:174-179.
34. van der Klaauw A.A., van der Straaten T., Baak-Pablo R., Biermasz N.R., Guchelaar H.J., Pereira A.M., Smit J.W., Romijn J.A. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. J. Clin. Endocrinol. Metab. 2008, 93:2828-2834.
35. Merola B., Cittadini A., Colao A. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J. Clin. Endocrinol. Metab. 1993, 77:1658-1661.
36. Valcavi R., Gaddi O., Zini M., Iavicoli M., Mellino U., Portioli I. Cardiac performance and mass in adults with hypopituitarism: effects of 1year of growth hormone treatment. J. Clin. Endocrinol. Metab. 1995, 80:659-666.
37. Caidahl K., Edén S., Bengtsson B.-A. Cardiovascular and renal effects of growth hormone. Clin. Endocrinol. 1994, 40:393-400.
38. Cenci M.C.P., Soares D.V., Spina L.D.C., Brasil R.R.L.O., Lobo P.M., Mansur M.A., Gold J., Michmacher E., Vaisman M., Conceição F.L. Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency. Pituitary 2009, 12:322-329.
39. Johannsson G., Rosén T., Lindstedt G., Bosaeus I., Bengtsson B.-A. Effects of two years of growth hormone treatment on body composition and cardiovascular risk factors in adults with growth hormone deficiency. Endocrinol. Metab. 1996, 3(Suppl. A):12.
40. Thuesen L., Jørgensen J.O.L., Müller J.R., Bø Kristensen, Skakkebæk N.E., Vahl N., Cristiansen J.S. Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clin. Endocrinol. 1994, 41:615-620.
41. Newman C.B., Frisch K.A., Rosenzweig B., et al. Moderate doses of hGH (0.64mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function. J. Clin. Endocrinol. Metab. 2011, 96:122-132.
42. Climent V.E., Picó A., Sogorb F., Aznar S., Lip G.Y., Marin F. Growth hormone therapy and the heart. Am. J. Cardiol. 2006, 97:1097-1102.